Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,189 | 853 | 4,233 |
| Samples | 1,763 | 391 | 1,348 |
| Peptides | 1,727 | 340 | 1,436 |
Function
TNXB · Tenascin XB
This gene encodes a member of the tenascin family of extracellular matrix glycoproteins. The tenascins have anti-adhesive effects, as opposed to fibronectin which is adhesive. This protein is thought to function in matrix maturation during wound healing, and its deficiency has been associated with the connective tissue disorder Ehlers-Danlos syndrome. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6. It is one of four genes in this cluster which have been duplicated. The duplicated copy of this gene is incomplete and is a pseudogene which is transcribed but does not encode a protein. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
9 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000644971 | P22105 | 2,475 | 1,662 |
| ENST00000375244 | P22105 | 2,116 | 1,497 |
| ENST00000479795 | C9J7W4* | 331 | 257 |
| ENST00000451343 | P22105-2 | 240 | 149 |
| ENST00000546684 | - | 23 | 19 |
| ENST00000383159 | A0A140T8Y3* | 1 | 1 |
| ENST00000433037 | A0A140T923* | 1 | 1 |
| ENST00000451159 | A0A140T956* | 1 | 1 |
| ENST00000549232 | A0A140TA52* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 1703 amino-acid changes on canonical ENST00000644971 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TNXB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TNXB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| Melanoma | 40/210 19% | 231/1899 12% |
| Endometrial Carcinoma | 19/42 45% | 56/612 9% |
| Squamous Cell Lung Carcinoma | 14/57 25% | 55/810 7% |
| Non-Small Cell Lung Carcinoma | 50/304 16% | 63/1390 5% |
| Acute Myeloid Leukemia | 6/90 7% | 0/0 0% |
| Colorectal Carcinoma | 38/143 27% | 180/3239 6% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Gastric Carcinoma | 5/74 7% | 91/1809 5% |
| Neuroendocrine Tumour | 31/154 20% | 6/577 1% |
| Cervical Carcinoma | 5/35 14% | 18/422 4% |
| Other Solid Cancers | 8/94 9% | 71/1515 5% |
| Bladder Carcinoma | 3/58 5% | 46/956 5% |
| Plasma Cell Myeloma | 12/44 27% | 4/305 1% |
| Thyroid Gland Carcinoma | 7/45 16% | 68/1592 4% |
| Germ Cell Tumour | 5/25 20% | 3/169 2% |
| Small Cell Lung Carcinoma | 2/9 22% | 29/752 4% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Ewings Sarcoma | 8/63 13% | 3/262 1% |
| Head and Neck Carcinoma | 7/85 8% | 46/1574 3% |
| Other Sarcomas | 11/69 16% | 10/699 1% |
| Biliary Tract Carcinoma | 2/54 4% | 25/950 3% |
| Burkitts Lymphoma | 6/32 19% | 0/196 0% |
| Adrenocortical Carcinoma | 0/3 0% | 3/112 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Ovarian Carcinoma | 11/109 10% | 16/998 2% |
| Hepatocellular Carcinoma | 4/46 9% | 50/2210 2% |
Mutation Distribution
Where TNXB is mutated · all tissues, split by cell line vs tissue
How many mutations in TNXB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,189 mutations in TNXB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|